Fovista AMD Failure Puts Eylea In The Clear, Blurs Anti-PDGF Prospects

The failure of two Phase III Fovista and Lucentis combination trials in treating wet AMD probably lifts the threat of shifts towards PDGF/VEGF combinations and thereby leaves Regeneron's Eylea sales in the clear.